NEW YORK (GenomeWeb) — Australian diagnostics firm Genetic Technologies said today that it has signed a memorandum of understanding to commercialize its range of polygenic risk tests in the US with the Translational Genomics Research Institute.
Under the terms of the deal, the partners will work together on a US commercialization strategy for Genetic Technologies' existing polygenic risk tests — which include its BrevaGenplus breast cancer risk assessment test — and future tests for indications in oncology, cardiovascular disease, and diabetes.
Genetic Technologies and Phoenix, Arizona-based TGen will also establish a joint US-based CLIA laboratory to offer the tests and work together to raise the funding necessary to support their alliance.
Additional terms were not disclosed.
"We are excited to be working with such a prestigious organization as TGen in bringing our current and developing future polygenic risk tests to the US market," Genetic Technologies Chairman Paul Kasian said in a statement.
Last summer, Genetic Technologies partnered with Beijing Zishan Health Consultancy on the establishment of a joint venture to offer its tests in China.